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Abstract
Influenza A viruses causes a variety of illnesses in humans. The most common infection, seasonal
influenza, is usually a mild, self-limited febrile syndrome, but it can be more severe in infants, the
elderly, and immunodeficient persons, in whom it can progress to severe viral pneumonitis or be
complicated by bacterial superinfection, leading to pneumonia and sepsis. Seasonal influenza also
occasionally results in neurologic complications. Rarely, viruses that have spread from wild birds to
domestic poultry can infect humans; such “avian influenza” can range in severity from mild
conjunctivitis through the rapidly lethal disease seen in persons infected with the H5N1 virus that
first emerged in Hong Kong in 1997. To develop effective therapies for this wide range of diseases,
it is essential to have laboratory animal models that replicate the major features of illness in humans.
This review describes models currently in use for elucidating influenza pathogenesis and evaluating
new therapeutic agents.
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I. Introduction
Influenza A viruses infecting humans are responsible for a gamut of illnesses ranging from
inapparent infections to pneumonia and severe acute respiratory syndrome. The typical
infection one associates with seasonal influenza is a mild, self-limited febrile syndrome. As
with other respiratory viruses, influenza viruses can cause more severe infections in infants,
the elderly, and immunodeficient persons. In those individuals whose immune system is
compromised or not fully developed, influenza-associated disease will often lead to severe
viral pneumonitis or be complicated by bacterial superinfection, leading to pneumonia and
sepsis. Seasonal influenza also occasionally results in neurologic complications. Even in non-
pandemic years, more than 40,000 deaths annually are attributable to influenza infections in
the United States (Dushoff et al., 2006). Much more rarely, humans can become infected by
viruses that have spread directly from wild birds to domestic poultry. Such “avian influenza”
can range in severity from mild conjunctivitis through the rapidly lethal disease seen in persons
infected with the recently emerged Southeast Asian H5N1 virus. However, the potential for
such highly virulent, lethal viruses to spread globally, as in the 1918 “Spanish Flu” pandemic,
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has resulted in a tremendous effort to develop vaccines and antiviral drugs to block the spread
of virus and to treat the disease in humans, so as to prevent death.
The basic virology, clinical syndromes, epidemiology, and approved antiviral drugs for
influenza virus infections are presented in Table 1. Efforts have intensified in recent years to
understand the pathogenesis of the various forms of influenza virus infection and to develop
new treatments (Beigel and Bray, 2008). To develop effective antiviral therapies for this wide
range of diseases, it is essential to have laboratory animal models that replicate the major
features of illness in humans and provide selective, sensitive and reproducible results. Selecting
the appropriate laboratory animal infection is very important in the drug development process.
Some animals, such as pigs and ferrets, are naturally susceptible to infection by influenza
viruses, but some of the other species that have been used for influenza studies are not. For the
latter, the virus requires adaptation before it can replicate in the animal and/or cause disease
(e.g., human seasonal influenza viruses in mice, rats). Once influenza viruses infect an animal,
the virus may cause nonlethal disease or lethal disease. The type of disease that is induced can
be manipulated by the investigator and is dependent on a variety of factors including virus
strain, amount of virus in the inoculum, route of inoculation, time allowed for the disease to
develop and the animal’s immune status.
This paper reviews animal models currently in use for the study of influenza pathogenesis and
immune responses to influenza virus infections and to assess vaccine and antiviral drug
efficacy. Models that will be reviewed will include: models of benign influenza, typical severe
seasonal influenza and pneumonia, influenza-associated sepsis, models using H5N1 viruses,
models in which acute respiratory distress syndrome (ARDS) is induced, models of influenza-
associated neurologic disease, models for virus transmission studies, immunocompromised
models, and models of host resistance.
II. Seasonal influenza
A. Models of benign influenza
Influenza is usually an acute, self-limited respiratory tract infection that begins with the sudden
onset of high fever, followed by inflammation of the upper respiratory tree and trachea, with
coryza, cough, headache, prostration, malaise and other signs and symptoms that persist for
7–10 days (Taubenberger and Morens, 2008). The virus replicates in both the upper and lower
respiratory tract. In experimental infections in healthy volunteers, influenza A viral replication
peaks approximately 48 hours after inoculation into the nasopharynx, declining thereafter, with
usually little or no virus shed after six days. However, viral antigen can still be detected in cells
from the respiratory tract and secretions of infected individuals by enzyme immunoassay for
several days after infectious virus can no longer be recovered (Wright et al, 2007). A summary
of current animal models available for studying benign seasonal influenza is presented in Table
2.
1. Mice
In mice infected with influenza viruses of low pathogenicity, a mild illness occurs with few of
the signs and symptoms that are seen in humans. The major parameters of mild to moderate
disease are weight loss and the detection of virus, primarily in the lungs (Sidwell and Smee,
2004). In such a model, a polymer-bound 6′ sialyl-N-acetyllactosamine was found to ameliorate
weight loss in treated animals (Gambaryan et al., 2005).
2. Ferrets
Less virulent strains of influenza virus cause mild influenza-like symptoms in ferrets that rarely
end in death. For example ferrets infected with A/Aichi/2/68 (H3N2) did not lose weight
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(Svitek et al., 2008). Only mild respiratory disease occurred in Aichi-infected animals with
occasional sneezing and little serous nose exudate expressed. Virus infection elicits a rapid and
strong upregulation of IFNα, IFNγ, and TNFα, while more virulent strains induced significantly
lower levels of IFNα during the first two days after infection. During the first four days after
infection, only IL-8 was detected in samples from animals inoculated with A/Aichi/2/68,
whereas IL-6 expression was associated with the more virulent viruses (Svitek et al., 2008).
The utility of a ferret model in which a benign infection was induced is illustrated by the results
from the following vaccine study. Ferrets immunized with virosome-based intranasal influenza
vaccine consisting of hemagglutinins from influenza A/Beijing/262/95like (H1N1), A/Sydney/
5/97 (H3N2), and influenza B/Harbin/7/94 and then challenged with the A/Sydney/5/97
(H3N2) strain had less viral shedding in nasal secretions and the vaccine elicited a vaccine-
specific antibody response (Lambkin et al., 2004). In addition, the vaccine regimen protected
against fever, weight loss, and infiltration of inflammatory cells.
3. Rats
“True” rat species have been evaluated to determine their suitability as models for influenza
disease and to ascertain whether genetic background impacts their susceptibility to infection.
In one study, Brown Norway (BN), Fischer-344 (F344) and Sprague–Dawley (SD) rats were
challenged with a rat-adapted influenzaA/Port/Chalmers/173 (H3N2) virus (Daniels et al.,
2003). The virus was adapted to rats by 11 successive passages thorough infected lung
homogenate. The F344 and SD rats were most sensitive to the infection, with 100-fold higher
lung virus titers than seen in the BN rats. Alveolar macrophages, lactate dehydrogenase activity,
and total lung protein concentrations (an indicator of pulmonary edema) were higher in the BN
rats. Neutrophil numbers, interleukin 6 levels, and TNFα activity were greatest in the
bronchoalveolar lavage fluids from F344 and SD rats. Nevertheless, the infection was not lethal
and few pathologic abnormalities were noted in the lungs. Although the study provided insights
into factors of importance in protecting the host from influenza virus infections, rat models
probably have not been characterized well enough to be recommended for use in evaluating
anti-influenza therapies.
Recently Alarcon et al. (2007) demonstrated the use of the Brown Norway rat in evaluating
influenza vaccines. Using microneedle technology for i.d. administration of three different
types of influenza vaccines (Fluzone® 2003–2004 formulations and DNA plasmid-based
vaccine) the investigators demonstrated in a rat model, that a whole inactivated virus elicited
antibody responses to the corresponding wild type parent H3N2 and B strains. Animals treated
with multiple doses of DNA plasmid vaccine also responded with antibody response to the
parent strains.
4. Pigs
Because influenza A viruses frequently adapt to efficient transmission among pigs, these
animals have occasionally been used as a model for testing vaccines (van der Laan et al.,
2008). Signs of illness include fever, loss of appetite, labored breathing and coughing.
However, the animals rarely die from the disease unless virus is directly inoculated into the
trachea, in which case they exhibit signs of pneumonia. Pigs have been found to have low
susceptibility to recently emerged H5N1 strains (Lipatov et al., 2008). To date, the main use
of the pig has been in the development of vaccines against swine influenza (reviewed by van
der Laan et al., 2008).
Problems that may preclude the use of pigs for influenza studies include caging, the
complexities of animal husbandry and waste management. Thus, the recent development of a
model in Ellegaard Göttingen minipigs appears to offer an alternative, if these animals can be
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shown to develop a fulminant pneumonia using a less intrusive route than intratracheal
inoculation. However, as in the case of common pigs, minipigs were not susceptible to infection
with H5N1 strains such as A/chicken/Yamaguchi/7/04 (Isoda et al., 2006). As with normal
pigs one must always be cautious to obtain animals with no previous exposure to influenza
viruses, since minipigs can be hosts for swine influenza A viruses (Hansen et al., 1997).
5. Nonhuman primates
Because nonhuman primates are much more closely related to humans than small animals
typically used to study influenza, they have been used as models for human disease. In
particular, rhesus macaques have been used to study pathogenesis and evaluate therapeutic and
prophylactic strategies (see Baas et al., 2006 for review). In addition, the suitability of pigtailed
macaques as models of influenza in the context of transcriptional studies has been evaluated
(Baskin et al. 2004). A recent study examined the innate immune response in affected lung
tissue with viral genetic material present (Baas et al., 2006). The authors used histopathological
analysis of lung tissue, immunohistochemistry, viral and host gene expression by microarray
analysis, proteomics, gene expression in circulating blood cells, and quantitative real-time RT-
PCR to study individual animal responses until the end of the experiment. The infections were
mild, without pneumonia or significant lung pathology. The investigators were able to
demonstrate significant differences in gene expression within regions in influenza virus-
induced lesions, based on the presence or absence of viral mRNA, and correlated them with
transcriptional markers of early disease in peripheral white blood cells (Baas et al., 2006).
The use of viruses causing benign infections in macaques has primarily been used for vaccine
studies. For example, Rimmelzwaan et al. (2001) demonstrated that protective immunity
induced by immune stimulating complex (ISCOM)-based vaccines consisting of the membrane
glycoproteins of A/Philippines/2/82 did not protect macaques from a challenge infection with
A/Netherlands/18/94. However, vaccination of monkeys, which had had a prior infection with
an influenza A/Philippines/2/82-like virus with a single dose of ISCOM vaccine, induced long-
lasting protective antibody immunity against challenge infection with the homologous virus
A/Netherlands/18/94.
B. Models of severe seasonal influenza and pneumonia
Occasionally in healthy individuals, but much more often in the very young, the elderly, and
the immunocompromised, acute seasonal influenza develops into hemorrhagic bronchitis and
viral pneumonia, characterized by dyspnea, hemoptysis, pulmonary edema and cyanosis. Death
can occur within 48 hours after the onset of symptoms. A summary of animal models available
to study such infections is presented in Table 3.
In cases of severe influenza pneumonia in humans, histological changes in the lungs include
capillary and small vessel thromboses, necrotizing bronchitis and bronchiolitis, interstitial
edema and inflammatory infiltrates, the formation of hyaline membranes in alveoli and alveolar
ducts, varying degrees of acute edema between the alveoli with or without hemorrhaging, and
diffuse alveolar damage. The later stages of the disease are characterized by organizing diffuse
alveolar damage, fibrosis, epithelial regeneration, and squamous metaplasia. If concomitant
bacterial or fungal infection is present, there may be pronounced neutrophil infiltration into
alveolar air spaces, with a lesser degree of alveolar hemorrhage and edema than in primary
influenza pneumonia (Taubenberger and Morens, 2008).
1. Mice
The mouse remains the primary model for evaluating the antiviral therapy of influenza
pneumonia, due to the inexpensiveness of the animals and their caging and the general fidelity
of the illness in mice to the human disease (Sidwell and Smee, 2004). In addition, many reagents
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are available to study the effects of virus replication and treatment on the mouse immune
system. The laboratory mouse can be experimentally infected with both seasonal influenza A
viruses and influenza B viruses, but this usually requires some adaptation by multiple lung
passage. The adapted virus can then infect murine lung cells, probably as a result of amino acid
changes in the surface hemagglutinins that enable it to bind to cell-surface alpha 2,3-linked
sialic acid molecules (Ibricevic et al., 2006). A recent advance in influenza A modeling has
been the finding that the reconstructed 1918 pandemic influenza virus is lethal for mice (Jeffery
et al., 2001; Taubenberger, 2006).
A number of parameters may be used to monitor influenza virus infection in mice, including
change in body weight, decline in arterial oxygen saturation, increase in serum alpha-1-acid
glycoprotein, mean time to death, and lung weight, viral titer and pathology scores (Sidwell
and Smee, 2000). Disease manifestations often depend on the infectivity and challenge dose
of the virus and (for seasonal influenza virus strains) how well the virus has adapted to the
host. If a virus replicates in mice without causing apparent illness, the effects of therapy can
be monitored using parameters such as lung viral titers, increase in lung weight and increase
in 1-acid glycoprotein (1-AG), all of which increase in nonlethally infected mice (Ottolini et
al., 2005; Sidwell and Smee, 2000).
Most of the histopathological features of influenza viral pneumonia listed above are also seen
in mice, but some signs and symptoms of human influenza are rarely observed. Mice do not
show outward signs of fever and do not have increased rectal temperatures, nor is dyspnea,
cyanosis or hemoptysis easily, if ever detected in mice infected with strains other than the
H5N1 virus. However, as in humans, reduced blood oxygen saturation levels, a measure of
lung function, can be measured in mice, and these levels are dramatically lower as pneumonia
progresses and the mice approach death (Barnard et al., 2007). Weight loss is also a good
marker of disease severity (Sidwell and Smee, 2000). The reader is referred to the following
recent papers that show the utility of the seasonal influenza mouse model for evaluating
vaccines (reviewed by van der Laan et al., 2008; Hagenaars et al., 2008; Hai et al.; 2008) and
antiviral drugs (Dimmock et al., 2008; Gilbert and McLeay, 2008; Reading et al., 2008; Smee
et al., 2008; Wang et al., 2008).
2. Ferrets
Because influenza-virus-infected ferrets develop many of the typical signs of infection in
humans, including nasal discharge, anorexia, watery eyes, otologic symptoms and fever, they
are now being used as an animal model for influenza-like pneumonia (Sidwell and Smee,
2000; Govorkova et al., 2007; Smee et al., 2008; Svitek et al., 2008). Virus in high titers can
be recovered from the respiratory tract (Smith and Sweet, 1988; Potter et al., 1976). Although
ferrets mimic seasonal influenza A infections in humans, they appear to be less responsive to
infections by influenza B viruses (Pinto et al., 1969).
A limitation of ferret studies is the lack of specific reagents for studying the ferret immune
system, compared with similar resources for mice. However, this issue will probably be
resolved in the near future with the development of reagents such as cross-reactive monoclonal
antibodies (mAb). For example, CD8+ cells in mouse bronchoalveolar lavages from
pneumonic ferrets were identified with mAb to human CD8 (Rutigliano et al., 2008). Caging
can also be a problem, because most animal facilities require that 1–3 ferrets be housed in
rabbit-style cage systems. Proper caging for work with H5N1 influenza virus is at the final
stages of development, but not yet available for use. Access to specific pathogen-free (influenza
virus seronegative) ferrets is also an issue, and will become increasingly so as the demand for
ferret studies grows. Finally, although ferrets are relatively passive in temperament relative to
their mink cousins, they can become fairly aggressive after being exposed to invasive
procedures.
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As a result of the studies described above, a number of studies have been done to show the
adequacy of ferrets as models for testing vaccine efficacy (reviewed by van der Laan et al.,
2008; {Huber, 2008 #4356;Parks, 2007 #4357} and the effectiveness of antiviral drug therapy
(Smee et al., 2008; Oxford et al., 2007; Malakhov et al., 2006).
3. Cotton rats
Cotton rats (Sigmodon hispidus) have several advantages over mice and ferrets as a model for
human influenza, including the availability of reagents to study immunological responses.
When compared to mice of any strain, cotton rats appear to have all the innate and adaptive
immune responses seen in humans, such as Mx gene-mediated responses. Viruses isolated from
humans do not have to be adapted to cotton rats to cause disease (Eichelberger, 2007). The
disadvantages of the cotton rat are primarily animal availability and the aggressiveness of
species, regardless of gender.
The influenza A cotton rat model is a nasal and pulmonary infection in adult inbred cotton rats.
Animals infected intranasally with doses of a recent H3N2 influenza strain had increased
breathing rates accompanied by weight loss and decreased temperature (Ottolini et al., 2005).
Virus replication peaked within 24 h in the lung, with peak titers proportional to the infecting
dose. Although virus was cleared from the lung by day 3, replication persisted in nasal tissues
for 6 days. Pulmonary pathology included early bronchiolar epithelial cell damage, followed
by extensive alveolar and interstitial pneumonia detectable in animals for up to about three
weeks. Cytokine levels were typical of an inflammatory response to a lung infection; their
upregulation appeared to coincide with increased virus replication. Since this model has not
been gained wide acceptance due to the limitations described above, there are a paucity of
papers using cotton rats to vaccine efficacy (Straight et al., 2008) and antiviral efficacy
(Eichelberger et al., 2004; Stertz et al., 2007) against influenza virus infections.
III. Models of influenza-associated sepsis
Although influenza virus by itself can cause pneumonia, secondary bacterial pneumonia
beginning either during or shortly after recovery from the primary virus infection is much more
common (Speshock et al., 2007). Co-infections with bacteria in seasonal influenza pandemics
have been associated with approximately 25% of all influenza-related deaths (Gupta et al.,
2008). A recent paper concluded “that influenza A virus infection in conjunction with bacterial
infection led to most of the deaths during the 1918–1919 pandemic” (Morens et al., 2008). A
number of animal models have been developed to evaluate the susceptibility of influenza-
infected individuals to bacterial superinfections, such as those caused by Neisseria
meningitidis (Alonso et al., 2003) and Streptococcus pneumoniae (Hayashi et al., 2006; Peltola
et al., 2006; Rosseau et al., 2007; Smith et al., 2007) (Table 4). Thus, efforts have been
undertaken to establish animal models to mimic influenza infections complicated by bacterial
infections, primarily pneumonia (McCullers and English, 2008).
Sun and Metzger (2008) recently proposed a mechanism whereby secondary bacterial infection
can occur. They found that interferon-gamma produced in the lungs of mice during T-cell
responses to influenza virus infection inhibited bacterial clearance by alveolar macrophages.
The higher the levels of interferon-gamma, the greater the suppression of phagocytosis, leading
to enhanced susceptibility to secondary pneumococcal infection.
A. Pneumococcal superinfection
The infectious agent most often complicating influenza is Streptococcus pneumoniae. In a
superinfection model, pneumococcal pneumonia after influenza virus infection was established
in six-week old mice using sublethal doses of both microbes (Hayashi et al., 2006). S.
pneumoniae was inoculated intranasally 7 days after exposure to influenza virus and death in
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the presence of both agents only began at day 4 post bacterial exposure. The efficacy of several
quinolones against bacteria-induced pneumonia in this model was evaluated, with gatifloxacin
used successfully to treat the pneumococcal infection.
In another model of secondary pneumococcal pneumonia during influenza A virus infection,
the pathology and immunology that led to fatal disease was studied by specifically looking at
cytokine profiles (Smith et al., 2007). Influenza-infected mice challenged with each of 3
serotypes of S. pneumoniae developed a severe, necrotic pneumonia, characterized by
markedly elevated levels of both pro- and anti-inflammatory molecules in the lungs,
accompanied by a massive influx of neutrophils. Death was associated with the development
of pneumonia and lung inflammation, but not with bacteremia. Thus, this model may be used
to delineate factors associated with the pathogenesis of severe mixed lung infections.
B. Meningococcal superinfection
In the meningococcal superinfection model, BALB/c mice were inoculated intranasally with
a sublethal dose of mouse-adapted influenza A/Scotland/20/74 (H3N2), followed by intranasal
inoculation with Neisseria meningitidis serogroup C (Alonso et al., 2003). Fatal meningococcal
pneumonia and bacteremia were observed in influenza-infected mice superinfected with
bacteria on day 7, but not on day 10. Thus, the investigators were able to model human
meningococcemia with fatal sepsis, and were also able to examine the role of various bacterial
virulence factors leading to sepsis.
C. Secondary bacterial infection in ferrets
A bacterial superinfection model was also established in ferrets, in which influenza more
closely resembles that found in humans (Peltola et al., 2006). The goals of the study were to
better understand the various sequelae of S. pneumoniae infection, including otitis media,
sinusitis, and pneumonia, and to determine if the frequency and character of secondary
pneumococcal infections differed depending on the strain of influenza virus that preceded
bacterial challenge, as has been reported in humans. The viruses studied were A/Taiwan/1/86
(H1N1), the H3N2 viruses A/Sydney/5/97 and A/Fujian/411/02, and influenza B virus B/
Singapore/222/79. In seven-week-old ferrets inoculated intranasally with virus and 5 days later
with S. pneumoniae, all viruses increased bacterial colonization of the nasopharynx. However,
9 of 10 ferrets infected with H3N2 subtype influenza A viruses developed either sinusitis or
otitis media, while only 1 of 11 infected with an H1N1 virus or an influenza B virus did so.
These data support observations in humans that bacterial complication rates are higher during
seasons when H3N2 viruses predominate (Bhat et al., 2005). This animal model could be useful
for further study of the mechanisms that underlie viral-bacterial disease synergism.
Secondary infection by Staphylococcus aureus has also been evaluated in cotton rats (Braun
et al., 2007). Although S. aureus superinfections are a relatively rare complication of influenza,
the case fatality rate is extremely high. In addition, all three influenza pandemics of the 20th
century included cases of co-infection with S. aureus in healthier and younger patients (Braun
et al., 2007). Therefore, physiologic and pathologic changes in cotton rats infected with both
S. aureus and influenza A/Wuhan/359/95 (H3N2) was evaluated and compared to the
infections in cotton rats with each agent alone. Peribronchiolitis, interstitial pneumonitis as
well as alveolitis were observed. Although pathology scores began to decline in the co-infected
on day 7 p.i., they remained significantly higher than all other infected cohorts. This was true
even in the cohort co-infected with inactivated S. aureus and influenza virus. Co-infection
resulted in higher mortality than infection with either agent alone, and was associated with
more marked hypothermia, lung pathology an enhancement of proinflammatory cytokine
expression in the lungs (Braun et al., 2007). In addition, bacteremia was prolonged and bacterial
lung titers were higher in co-infected cotton rats.
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IV. H5N1 avian influenza
In contrast to the human-adapted influenza A viruses that cause benign seasonal influenza in
the majority of patients, the recently emerged Southeast Asian H5N1 virus causes acute viral
pneumonia aggravated by ARDS, toxic shock and multiple organ failure in previously healthy,
immunocompetent individuals (Peiris et al., 2007, Beigel, et al., 2005). Its markedly enhanced
virulence for humans appears at least in part to reflect a difference in viral tropism for cells of
the lower respiratory tract, but until recently, those target cells were unknown for both humans
and other mammals (Rimmelzwaan et al., 2006; van Riel et al., 2006). In a recent study (van
Riel et al., 2006), an H5N1 virus was found to preferentially bind to type II pneumocytes,
alveolar macrophages, and nonciliated bronchiolar cells in the lower respiratory tract of cats,
similar to the clinical scenario in humans (Matrosovich et al., 2004). How well various animal
models resemble human disease may thus reflect the difference in distribution of infection in
the respiratory tract. Because the H5N1 virus infects a wide range of mammalian species
without prior adaptation, a number of animal models are available for study (Table 5).
A. Mice
Isolates of H5N1 virus recovered from human patients can cause lethal disease in BALB/c
mice without prior adaptation (Evseenko et al., 2007; Hatta et al., 2007; Hatta and Kawaoka,
2005; Isoda et al., 2006; Katz et al., 2000b, Gubareva et al., 1998a). Although the infection is
primarily pulmonary, there is strong evidence of systemic spread to solid organs, including the
brain (Gubareva et al., 1998a; Katz et al., 2000a). Most of these viruses cause necrosis in
respiratory epithelium of the nasal cavity (Hatta et al., 2007), trachea (Hatta et al., 2007),
bronchi, and bronchioles (Katz et al., 2000b, Hatta and Kawaoka, 2005) with accompanying
inflammation and accumulation of fibrin and neutrophils (Katz et al., 2000b). The pathology
in the lungs can be characterized as a peribronchial alveolitis with intra-alveolar serofibrinous
exudate, erythrocytes and neutrophils, and increased numbers of alveolar macrophages (Katz
et al., 2000b). Often the infection results in a bronchointerstitial pneumonia and alveolar edema
or in severe cases it may become a diffuse interstitial pneumonia affecting entire lung lobes
(Dybing et al., 2000). Body temperatures usually decrease by four of five degrees and animals
lose at least 20% or more body when they succumb to the effects of the infection.
In another study, a recent H5N1 isolate was shown to promote significantly higher levels of
pro-inflammatory cytokines in whole lungs and primary human macrophages probably
resulting in early and excessive infiltration of macrophages and neutrophils in the lungs of
mice (Perrone et al., 2008). Another study has suggested that in addition to the typical
proinflammatory cytokines, TNF-a may also contribute to the morbidity during H5N1
influenza virus infection (Szretter et al., 2007).
Because of the severity of H5N1 infections in humans caused by highly pathogenic avian
influenza viruses, numerous vaccine and antiviral efficacy studies have recently been done in
mice. See the following recent references for vaccine studies (reviewed by van der Laan et al.,
2008; Chen et al., 2008; Chen et al., 2009; Hickman et al., 2008; de Vries et al., 2008) and for
antiviral efficacy studies (Barnard et al., 2007; Boltz et al., 2008a; Ilyushina et al., 2008; Zheng
et al., 2008).
B. Ferrets
Two H5N1 viruses isolated in Hong Kong during the 1997 outbreak were found to readily
infect ferrets (Zitzow et al., 2002). Since then, more H5N1 isolates that are highly pathogenic
for birds have been found to replicate in ferret lungs without prior host adaptation. The
infections generally have been characterized by severe lethargy, fever, weight loss, transient
lymphopenia, and virus replication in the upper and lower respiratory tract and in multiple
organs including the brain. More importantly, the illness induced by these agents was more
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severe than that induced by recently isolated human H3N2 viruses. The lungs of H5N1-infected
ferrets showed diffuse inflammation of interalveolar septa with infiltrates of mononuclear cells
and intra-alveolar edema, regardless of the time post infection; in contrast to the scattered
infiltrates seen with other influenza A viruses, these changes were observed throughout the
lungs (Maines et al., 2005). Viral antigens were detected in alveolar bronchial cells or
bronchioles in the majority of animals by day 3 post virus exposure. Brain tissues showed
mononuclear cell infiltrates in the meninges, choroid plexus, and brain parenchyma, and viral
antigens were detected in neurons in the same areas.
In an effort to determine why the H5N1 virus is more virulent for ferrets than seasonal influenza
A isolates, Cameron et al. (2008) analyzed the expression of host innate immune response
genes during the course of lethal infection. The authors found that many interferon response
genes, including IFI44, ISG15 (G1P2), MX2, OAS1, OAS2, STAT1, TAP1, and UBE1L, were
significantly upregulated ferrets infected with the H5N1 virus, in comparison to an H3N2
isolate. CXCL10, a chemoattractant of activated Th1 lymphocytes and natural killer cells, was
also upregulated to a much greater extent in an H5N1 infection than with the H3N2 virus.
CXCL10 and its receptor CXCR3 are thought to play a role in the temporal development of
innate and adaptive immunity in concert with type I and II interferons (Neville et al., 1997).
In support of that hypothesis, Cameron et al. (2008) found that treatment of H5N1-infected
ferrets with AMG487, a CXCR3 antagonist, markedly reduced the severity of symptoms and
delayed death, compared to untreated animals.
Vaccines (reviewed by Subbarao and Luke, 2007; Chen at al. 2008; Lalor et al., 2008;
Mahmood et al., 2008;) and a number antiviral compounds (Malakhov et al., 2006; Govorkova
et al., 2007; Boltz et al., 2008b; Yun et al., 2008) have been tested in ferrets infected with H5N1
viruses very often have verified findings in mice (Malakhov et al., 2006; Govorkova et al.,
2007; Boltz et al., 2008b; Yun et al., 2008).
C. Cats
Rimmelzwaan et al. (2006) assessed the virulence of a H5N1 virus in cats by infecting them
by intratracheal inoculation or through feeding on virus-infected chicks. Within two days, most
animals developed fever, conjunctivitis, lethargy, and labored breathing. Virus was detected
in the throat, nasal, and rectum, regardless of the original site of infection. The virus spread
systemically and was detected in the respiratory and digestive tracts, liver, kidney, heart, brain,
and lymph nodes. Cellular damage in infected tissues correlated with the detection of viral
proteins. Histopathological examination of the lungs revealed multiple or coalescing foci of
inflammation and necrosis in the bronchioles. The alveolar and bronchiolar lumina were
infiltrated with alveolar macrophages, neutrophils, and erythrocytes, mixed with fibrin, edema
fluid, and cellular debris. More importantly, some alveoli were covered by hyaline membranes,
which are also seen human lungs upon autopsy. Hyaline membrane formation has not been
observed in mice or other animal models. The epithelium of bronchiolar and alveolar walls,
which were moderately thickened, also had evidence of both necrosis and hyperplasia. There
was also edema and moderate accumulation of mononuclear cells around pulmonary artery
branches. Although there has been some work in defining the cat influenza model for evaluating
pathogenesis of H5N1 infections, few if any studies have been published which describe the
suitability of the cat for doing vaccine (Karaca et al., 2005; Vahlenkamp et al., 2008) and
antiviral efficacy studies.
D. Dogs
Dogs can also be infected with the H5N1 avian influenza virus. Because these animals are
often in close contact with both wild and domestic birds and with humans, this raises the
possibility that the virus could adapt to dogs and be transmitted to humans while retaining
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virulence. To date it has been found that dogs are susceptible to experimental infection but are
not capable of transmitting the virus to other mammals (Giese et al., 2008). The disease in dogs
was characterized by the development of conjunctivitis and fever within 2 days after virus
exposure, which resolved with no other adverse events by day 7. Dogs may be useful more as
sentinel for human disease than as a model for human influenza disease (Cleaveland et al.,
2006).
E. Nonhuman primates
A cynomolgus macaque (Macaca fascicularis) model of H5N1 (A/HongKong/156/97) virus
infection with pneumonia and ARDS has been developed (Kuiken et al., 2003; Rimmelzwaan
et al., 2003). The principal change in the lung was a necrotizing bronchial interstitial
pneumonia, similar to that described for primary human influenza pneumonia. In contrast to
human H5N1 cases, detection of influenza virus antigen was limited to pulmonary tissue and
tonsils. The model was used to evaluate the efficacy of intravenous zanamivir, which has a
longer half-life than oseltamivir (Stittelaar et al., 2008). Drug levels in the epithelial lining
fluids of the lungs were equivalent to those in plasma. Treated macaques had lower gross
pathology scores and less lung pathology than untreated animals. However, there was
considerable variability in viral lung titers and gross pathology within groups of macaques,
and scattering of foci of lung infection from animal to animal, making it difficult to establish
statistically significant differences. The authors pointed out that such variability probably
reflects what happens within the human population. Some vaccine studies with macaques have
also been done (de Vries et al., 2008; Kreijtz et al. 2008; Ruat et al., 2008 among others).
V. Models of ARDS
ARDS is characterized by a localized hyperinflammatory response to an infectious agent in
the lung, resulting in damage to the alveolus–capillary interface (Hammerbeck et al., 2007).
H5N1 virus-infected humans initially present with clinical signs of influenza-like illness, then
develop progressive pneumonia and may eventually die of ARDS (Grose and Chokephaibulkit,
2004). Thus, some research has been done to develop a model of ARDS in H5N1 virus-infected
mice.
In one ARDS model using 6- to 8-wk-old BALB/c mice inoculated intranasally with influenza
virus A H5N1 (A/Chicken/Hebei/108/2002), the animals developed typical ARDS, with highly
edematous lungs, dramatic increases in lung weights, progressively more hypoxemia and 80%
mortality by day 8 (Xu et al., 2006). Histological examination revealed inflammatory cell
infiltrates in the alveoli with a significant increase in neutrophils, interstitial edema and
hemorrhage. Levels of TNF-a and L-6 in bronchiolar lavage fluids were significantly increased.
The model thus displayed some of the more significant signs and symptoms associated with
ARDS in humans. A summary of current animal models available for studying ARDS in H5N1
influenza is shown in Table 6.
VI. Models of influenza-associated neurologic disease
Because a number of studies have described neurological sequalae from influenza virus
infections, an animal model in which such complications can be studied and treatment can be
tested would be of importance (Mizuguchi et al., 2007; Steininger et al., 2003). A summary of
current animal models available for studying influenza virus-associated neurotropic disease is
presented in Table 7.
A. Seasonal influenza
Mori et al. (2002) have used a highly neurovirulent recombinant R404BP strain of influenza
A (H1N1) virus to test amantadine therapy in mice. Stereotaxic microinjection of virus into
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the olfactory bulb of the animal results in outward spread to neurons in broad areas of the brain
parenchyma, leading to apoptotic neurogeneration and fatal edema, beginning on day eight.
However, amantadine treatment beginning as late as seven days after virus injection protected
the animals. The disadvantage of this clinically relevant model is that only researchers having
stereotaxic microinjection equipment could use it.
A second study in mice used a neurovirulent A/WSN/33 strain of H1N1 influenza A virus
administered intranasally, resulting in infection of olfactory neurons and anterograde axonal
transport to the olfactory bulbs (Aronsson et al., 2003). Using immunodefective mutant mice
to examine how the immune system controls the spread and persistence of the virus, the authors
showed that an absence of T and B cells allowed the infection to spread fully into the brain.
B. H5N1 avian influenza
In a simplified neurovirulence model, Park et al. (2002) demonstrated that simple intranasal
instillation of influenza A (H5N1) virus isolated from a patient during the 1997 Hong Kong
outbreak could result in the infection of the murine central nervous system. After initial
replication in the respiratory mucosa, the virus apparently traveled through afferent fibers of
the olfactory, vagal, trigeminal, and sympathetic nerves, where it was detected by
immunohistochemical and in situ hybridization. This study demonstrates the feasibility of
using intranasal installation of viruses isolated directly from patients to establish an
encephalitis-like infection, an ideal way for quickly evaluating antiviral inhibitors.
Yun et al. (2008) injected peramivir intramuscularly into ferrets infected intranasally with the
highly neurovirulent A/Vietnam/1203/04 (H5N1) influenza virus and were able to show that
peramavir delivered in this manner ameliorated virus-induced disease by reducing infectious
virus titers in the lungs and brains and promoted survival in ferrets.
VII. Animal models for the study of drug-resistant influenza virus infections
The potential for influenza viruses to develop resistance to amantadine and rimantadine has
been well established in clinical studies (Monto and Arden, 1992; Hayden and Hay, 1992;
Englund et al., 1998) and in mice (Sidwell and Smee, 2003). By contrast, viruses that have
acquired resistance to zanamivir and oseltamivir generally display a significant reduction in
infectivity in mice, compared to the parent viruses (Gubareva et al., 2000; Herlocher., et al.,
2004; Yen et al., 2005). This reduction in virulence has been evaluated by several means. In
one study, mice were infected in parallel with equal quantities of the parental and the mutant
viruses, and lungs were removed early in the infection (Gubareva et al., 1997). The virus titer
in each was then determined and the titers of the challenge viruses needed to induce a 50%
infection were compared or the amount of virus produced in the lungs by equivalent
concentrations of the viruses was quantified (Tai et al., 1998). Alternatively, using a mouse-
adapted influenza virus, the relative virulence of the mutant virus was assessed using
parameters such as increased lung weight, lung pathogenesis scores, lung histopathology, and
decreased SaO2% levels of the lungs (Sidwell et al., 1995).
Ferrets have been used extensively to study the infectivity and virulence of influenza virus
mutants resistant to the neuraminidase inhibitors (Blick et al., 1998; Gubareva et al., 1998b;
Barnett et al., 2000). Blick et al. (1998) found that a zanamivir-resistant influenza virus with
an NA and HA mutation was not resistant to zanamivir in ferrets, even though a small decrease
in sensitivity to the drug had been shown in mice, indicating some potential differences in the
two models when studying drug-resistant viruses. A summary of current animal models
available for studying drug-resistant influenza virus infections is presented in Table 8.
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VIII. Models of influenza in the immunocompromised host
Influenza can be particularly serious in individuals with congenital or acquired
immunodeficiency because of aging, cancer treatment, organ transplantation, or human
immunodeficiency virus infection (Lee and Barton, 2007). It is therefore important to have
models in which to evaluate the effects of chemotherapy on influenza virus infections in
immunosuppressed animals (Table 9).
Cyclophosphamide treatment has been used to immunosuppress mice to assess the efficacy of
a neuraminidase inhibitor (peramivir) in an immunocompromised host (Sidwell et al., 2003).
Cyclophosphamide was injected intraperitoneally at a dose of 100 mg/kg every four days for
varying lengths of time. Peramivir was capable of significantly ameliorating the influenza virus
infection in mice immunosuppressed by short-term or prolonged cyclophosphamide therapy.
Severe, combined immunodeficient (SCID) mice also provide a model for evaluating anti-
influenza treatments in an immunocompromised host. In a recent study, SCID mice infected
with an influenza A virus and treated with either oral oseltamivir or the experimental compound
A-322278 showed reduced viral replication, limited weight loss and prolonged survival, so
long as the treatments persisted (Sidwell et al., 2003). However, once treatment was
discontinued, the animals had detectable, progressive viral replication with subsequent clinical
decline. More importantly, drug-resistant virus was detected in the chronically infected, drug-
treated mice, but not in the placebo-treated animals that died rapidly from infection.
IX. Models of host resistance (immunocompetence after therapy)
Effective immune clearance of influenza virus requires an immune system that is intact and
functioning normally. Host resistance models have therefore been used to evaluate the effect
of an antiviral treatment on virus clearance, as an indicator of the immunocompetence of an
animal during or after treatment and to test for the immunotoxicity of a particular agent
(Burleson and Burleson, 2007). Mechanistic studies to detect immunotoxicity should include
measuring innate, humoral and cell mediated immune responses, through parameters such as
cytokine and interferon production, macrophage function, and natural killer cell function and
cytotoxic T lymphocyte activity, as well as influenza-specific antibody during or after drug
treatment. For example, the compound 3M-011, a synthetic human TLR7/8 agonist, was
evaluated for antiviral efficacy and immunotoxicity in a rat HR model, which parallel human
influenza infection, both with respect to time course and development of respiratory tract
lesions (Hammerbeck et al., 2007; Burleson and Burleson, 2007). Intranasal (IN)
administration of 3M-011 significantly inhibited H3N2 influenza viral replication in the nasal
cavity when animals were pretreated or therapeutically treated with the compound. Inhibition
correlated closely with induction of type I interferon and to a lesser extent with other cytokines
such as TNF-α, IL-12, and IFN-γ from rat peripheral blood mononuclear cells, and seemed to
have no negative effect on the immune response to infection.
X. Animal models of influenza A virus transmission
To pose a significant threat to humans, a novel influenza A virus must be able to replicate in
the human respiratory tract and be transmitted efficiently from person to person. This is clearly
demonstrated by the recently emerged H5N1 avian influenza virus, which causes rapidly
overwhelming pneumonia, but has only rarely spread from a patient to close contacts. Animal
models have been developed to evaluate the pandemic potential of influenza viruses, especially
for the H5N1 agent. In one recent study, Yen et al. (2007) housed ferrets infected with a
neuraminidase inhibitor resistant recombinant A/Vietnam/1203/04 (H5N1) influenza virus
together with uninfected ferrets and monitored illness, detectable virus shedding lung viral
titers and death. They observed only limited transmission of infection to health contacts, which
correlated with low amounts of virus in respiratory secretions. The authors concluded that
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molecular determinants in addition to a virus’s receptor binding affinity were responsible for
influenza virus transmission among mammalian species (Yen et al., 2007).
The guinea pig has also been evaluated as a transmission model mammalian host for influenza
virus. Guinea pigs were found to be highly susceptible to infection with the unadapted virus
A/Panama/2007/99 (H3N2) virus, which replicated to high titers in the upper respiratory tract
(Lowen et al., 2006). Although the animals did not sneeze or cough, virus was shed in nasal
washings. In experiments performed at an ambient temperature of 20°C and under low
humidity, virus was transmitted from infected to non-infected guinea pigs housed either in the
same cage, in an adjacent cage, or in a cage placed 91 cm away. Transmission appeared to be
by droplet spread, and was more efficient at lower ambient temperature and humidity.
XI. Conclusion
As shown in this review, several species of laboratory animals have proved to be very useful
for research on influenza. Mice, particularly the BALB/c strain, are currently intensively
employed for studying pathogenesis, for demonstrating the efficacy of antiviral drugs, and for
preliminary efficacy studies for vaccines. Studies with antiviral agents have shown the
infection in mice to be predictive of efficacy in humans. For example, all of the currently
approved drugs for treating influenza virus infections were first shown to be efficacious in
mice. Although mice are not readily susceptible to newly isolated human seasonal influenza
viruses and require virus adaptation, many highly pathogenic avian influenza strains require
no adaptation and readily infect mice to cause lethal disease. Mice also do not exhibit some of
the clinical symptoms detected in humans such as nasal exudate, fever, sneezing, and coughing.
However, many clinical signs that seem to markers of disease severity can be measured in mice
to study influenza disease, such as saturated oxygen levels, virus lung titers, cytokine levels,
serum and acute phase proteins. In addition, the use of mouse models enable the investigator
to rapidly evaluate the efficacy of antiviral agents and vaccines at relatively lesser costs than
other animal models.
Ferrets are now being widely used to supplement or validate studies in mice, especially for
H5N1 virus studies in order to comply with new FDA “two animal rule”. A tremendous
advantage of ferrets is that these animals display many clinical symptoms of human influenza.
The model also has a similar complexity to that of humans. However, as with the mouse model,
many host factors found associated with humans are missing or have not yet been discovered
in the ferret. The costs of ferrets, space needed for housing, temperament of the animal once
handled experimentally, and the availability of animals without prior exposure to influenza
remain of concern.
The other animal species that could be used as models have not been sufficiently studied for
their suitability for routine use in studying influenza disease and influenza pathogenesis. In
addition, immune reagents for some of these other species remain yet to be developed. The
availability of some of the species is very limited, and the costs for housing and handling of
some of the larger species are great.
Despite the evidence of the great influenza pandemic of 1918, which brought about the death
of some 50 million people, influenza is often viewed as a “nuisance” disease, for which
adequate countermeasures are already available. However, the recent emergence of the highly
virulent H5N1 avian influenza virus in Southeast Asia has served as a wakeup call, reminding
the medical community that novel influenza A viruses can unexpectedly enter the human
population and that even the currently circulating seasonal strains are responsible for hundreds
of thousands of deaths worldwide each year. Influenza A viruses, far from being benign
respiratory pathogens, are a major public health problem that calls for a serious and sustained
research response. An essential part of that process is the development of laboratory animal
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models of influenza virus infection for the study of pathogenesis and the evaluation of new
drugs and vaccines. As described in this paper, a number of animal models have been
developed, but many gaps remain. Many of the current models remain incompletely
characterized, and none has been employed to its full potential. New and better models are
needed to provide more accurate answers to critical questions in pathogenesis and therapy. It
is hoped that this paper will contribute to the better use of laboratory animal models to combat
the continuing threat of influenza.
Acknowledgments
Some of data reviewed in this manuscript were from experiments supported by contract NO1-AI-15435 from the
Virology Branch, DMID, NIAID, NIH.
References
Alarcon JB, Hartley AW, Harvey NG, Mikszta JA. Preclinical Evaluation of Microneedle Technology
for Intradermal Delivery of Influenza Vaccines. Clin Vaccine Immunol 2007;14:375–81. [PubMed:
17329444]
Alonso JM, Guiyoule A, Zarantonelli ML, Ramisse F, Pires R, Antignac A, Deghmane AE, Huerre M,
van der Werf S, Taha MK. A model of meningococcal bacteremia after respiratory superinfection in
influenza A virus-infected mice. FEMS Microbiol Letters 2003;222:99–106.
Aronsson F, Robertson B, Ljunggren HG, Kristensson K. Invasion and persistence of the neuroadapted
influenza virus A/WSN/33 in the mouse olfactory system. Viral Immunol 2003;16:415–13. [PubMed:
14583155]
Baas T, Baskin CR, Diamond DL, Garcia-Sastre A, Bielefeldt-Ohmann H, Tumpey TM, Thomas MJ,
Carter VS, Teal TH, Van Hoeven N, Proll S, Jacobs JM, Caldwell ZR, Gritsenko MA, Hukkanen RR,
Camp DG II, Smith RD, Katze MG. Integrated Molecular Signature of Disease: Analysis of Influenza
Virus-Infected Macaques through Functional Genomics and Proteomics. J Virol 2006;80:10813–
10828. [PubMed: 16928763]
Barnard DL, Wong MH, Bailey K, Day CW, Sidwell RW, Hickok SS, Hall TJ. Effect of oral gavage
treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus
infections in mice. Antivir Chem Chemother 2007;18:125–32. [PubMed: 17626596]
Barnett JM, Cadman A, Gor D, Dempsey M, Walters M, Candlin A, Tisdale M, Morley PJ, Owens IJ,
Fenton RJ, Lewis AP, Claas EC, Rimmelzwaan GF, De Groot R, Osterhaus AD. Zanamivir
susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase
II clinical efficacy studies. Antimicrob Agents Chemother 2000;44:78–87. [PubMed: 10602727]
Baskin CR, Garcia-Sastre A, Tumpey TM, Bielefeldt-Ohmann H, Carter VS, Nistal-Villan E, Katze MG.
Integration of clinical data, pathology, and cDNA microarrays in influenza virus-infected pigtailed
macaques (Macaca nemestrina). J Virol 2004;78:10420–32. [PubMed: 15367608]
Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen
TH, Tran TH, Nicoll A, Touch S, Yuen KY. Avian influenza A (H5N1) infection in humans. N Engl
J Med 2005;353:1374–85. [PubMed: 16192482]
Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral
Res 2008;78:91–102. [PubMed: 18328578]
Blick TJ, Sahasrabudhe A, McDonald M, Owens IJ, Morley PJ, Fenton RJ, McKimm-Breschkin JL. The
interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-
guanidino-Neu5Ac2en. Virology 1998;246:95–103. [PubMed: 9656997]
Bhat N, Wright JG, Broder KR, Murray EL, Greenberg ME, Glover MJ, Likos AM, Posey DL, Klimov
A, Lindstrom SE, Balish A, Medina M-j, Wallis TR, Guarner J, Paddock CD, Shieh WJ, Zaki SR,
Sejvar JJ, Shay DK, Harper SA, Cox NJ, Fukuda K, Uyeki TM. the Influenza Special Investigations
T. Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med
2005;353:2559–67. [PubMed: 16354892]
Boltz DA, Ilyushina NA, Arnold CS, Babu YS, Webster RG, Govorkova EA. Intramuscularly
administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in
mice. Antiviral Res 2008a;80:150–7. [PubMed: 18573280]
Barnard Page 14
Antiviral Res. Author manuscript; available in PMC 2010 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Boltz DA, Rehg JE, McClaren J, Webster RG, Govorkova EA. Oseltamivir prophylactic regimens prevent
H5N1 influenza morbidity and mortality in a ferret model. J Infect Dis 2008b;197:1315–23.
[PubMed: 18422444]
Braun LE, Sutter DE, Eichelberger MC, Pletneva L, Kokai-Kun JF, Blanco JC, Prince GA, Ottolini MG.
Co-infection of the cotton rat (Sigmodon hispidus) with Staphylococcus aureus and influenza A virus
results in synergistic disease. Microb Pathog 2007;43:208–16. [PubMed: 17689046]
Burleson GR, Burleson FG. Influenza virus host resistance model. Methods 2007;41:31–37. [PubMed:
17161300]
Cameron CM, Cameron MJ, Bermejo-Martin JF, Ran L, Xu L, Turner PV, Ran R, Danesh A, Fang Y,
Chan PKM, Mytle N, Sullivan TJ, Collins TL, Johnson MG, Medina JC, Rowe T, Kelvin DJ. Gene
expression analysis of host innate immune responses during lethal H5N1 infection in ferrets. J Virol
2008;82:11308–17. [PubMed: 18684821]
Chen Q, Kuang H, Wang H, Fang F, Yang Z, Zhang Z, Zhang X, Chen Z. Comparing the ability of a
series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus
Genes. 2008Epub ahead of print
Chen Z, Santos C, Aspelund A, Gillim-Ross L, Jin H, Kemble G, Subbarao K. Evaluation of live
attenuated influenza a virus h6 vaccines in mice and ferrets. J Virol 2009;83:65–72. [PubMed:
18945773]
Cleaveland S, Meslin FX, Breiman R. Dogs can play useful role as sentinel hosts for disease. Nature
2006;440:605. [PubMed: 16572146]
Daniels MJ, Selgrade MK, Doerfler D, Gilmour MI. Kinetic profile of influenza virus infection in three
rat strains. Comp Med 2003;53:293–98. [PubMed: 12868575]
de Vries JJ, Bungener L, Ter Veer W, van Alphen L, van der Ley P, Wilschut J, Huckriede A.
Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes
increases vaccine immunogenicity. Vaccine. 2008Epub ahead of print
Dimmock NJ, Rainsford EW, Scott PD, Marriott AC. Influenza Virus Protecting RNA: an Effective
Prophylactic and Therapeutic Antiviral. J Virol 2008;82:8570–78. [PubMed: 18579602]
Dushoff J, Plotkin JB, Viboud C, Earn DJ, Simonsen L. Mortality due to influenza in the United States--
an annualized regression approach using multiple-cause mortality data. Am J Epidemiol
2006;163:181–7. [PubMed: 16319291]
Dybing JK, Schultz-Cherry S, Swayne DE, Suarez DL, Perdue ML. Distinct Pathogenesis of Hong Kong-
Origin H5N1 Viruses in Mice Compared to That of Other Highly Pathogenic H5 Avian Influenza
Viruses. J Virol 2000;74:1443–50. [PubMed: 10627555]
Eichelberger MC, Prince GA, Ottolini MG. Influenza-induced tachypnea is prevented in immune cotton
rats, but cannot be treated with an anti-inflammatory steroid or a neuraminidase inhibitor. Virology
2004;322:300–7. [PubMed: 15110527]
Eichelberger MC. The Cotton Rat as a Model to Study Influenza Pathogenesis and Immunity. Viral
Immunol 2007;20:243–49. [PubMed: 17603841]
Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, Yousuf H, Regnery H, Klimov
AI, Cox NJ, Whimbey E. Common emergence of amantadine- and rimantadine-resistant influenza
A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998;26:1418–24. [PubMed:
9636873]
Evseenko VA, Bukin EK, Zaykovskaya AV, Sharshov KA, Ternovoi VA, Ignatyev GM, Shestopalov
AM. Experimental infection of H5N1 HPAI in BALB/c mice. Virol J 2007;4:77. [PubMed:
17662125]
Gambaryan AS, Boravleva EY, Matrosovich TY, Matrosovich MN, Klenk HD, Moiseeva EV, Tuzikov
AB, Chinarev AA, Pazynina GV, Bovin NV. Polymer-bound 6’ sialyl-N-acetyllactosamine protects
mice infected by influenza virus. Antiviral Res 2005;68:116–123. [PubMed: 16214231]
Giese M, Harder TC, Teifke JP, Klopfleisch R, Breithaupt A, Mettenleiter TC, Vahlenkamp TW.
Experimental infection and natural contact exposure of dogs with avian influenza virus (H5N1).
Emerg Infect Dis 2008;14:308–10. [PubMed: 18258127]
Gilbert BE, McLeay MT. MegaRibavirin aerosol for the treatment of influenza A virus infections in mice.
Antiviral Res 2008;78:223–29. [PubMed: 18281104]
Barnard Page 15
Antiviral Res. Author manuscript; available in PMC 2010 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. Efficacy of Oseltamivir
Therapy in Ferrets Inoculated with Different Clades of H5N1 Influenza Virus. Antimicrob Agents
Chemother 2007;51:1414–24. [PubMed: 17296744]
Grose C, Chokephaibulkit K. Avian influenza virus infection of children in Vietnam and Thailand. Ped
Infect Dis J 2004;23:793–94.
Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the
neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol
1997;71:3385–90. [PubMed: 9094607]
Gubareva LV, McCullers JA, Bethell RC, Webster RG. Characterization of Influenza A/HongKong/
156/97 (H5N1) Virus in a Mouse Model and Protective Effect of Zanamivir on H5N1 Infection in
Mice. J Infect Dis 1998a;178:1592–96. [PubMed: 9815209]
Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir
resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998b;
178:1257–62. [PubMed: 9780244]
Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000;355:827–
35. [PubMed: 10711940]
Gupta RK, George R, Nguyen-Van-Tam JS. Bacterial pneumonia and pandemic influenza planning.
Emerg Infect Dis 2008;14:1187–92. [PubMed: 18680640]
Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D,
Vromans H, Jiskoot W. Head-to-head comparison of four nonadjuvanted inactivated cell culture-
derived influenza vaccines: Effect of composition, spatial organization and immunization route on
the immunogenicity in a murine challenge model. Vaccine 2008;26:6555–63. [PubMed: 18848856]
Hai R, Martinez-Sobrido L, Fraser KA, Ayllon J, Garcia-Sastre A, Palese P. Influenza B Virus NS1-
Truncated Mutants: Live-Attenuated Vaccine Approach. J Virol 2008;82:10580–90. [PubMed:
18768976]
Hammerbeck DM, Burleson GR, Schuller CJ, Vasilakos JP, Tomai M, Egging E, Cochran FR, Woulfe
S, Miller RL. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects
against influenza in rats. Antiviral Res 2007;73:1–11. [PubMed: 16959331]
Hansen AK, Farlov H, Bollen P. Microbiological monitoring of laboratory pigs. Lab Anim 1997;31:193–
200. [PubMed: 9230498]
Hatta M, Kawaoka Y. A clue to the molecular mechanism of virulence of highly pathogenic H5N1 avian
influenza viruses isolated in 2004. Uirusu 2005;55:55–61. [PubMed: 16308530]
Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, Nguyen T, Lien PS, Le QM, Kawaoka Y. Growth of
H5N1 Influenza A Viruses in the Upper Respiratory Tracts of Mice. PLoS Pathog 2007;3:1374–79.
[PubMed: 17922570]
Hayashi K, Kadowaki S-e, Takei M, Fukuda H. Efficacy of Quinolones against Secondary Pneumococcal
Pneumonia after Influenza Virus Infection in Mice. Antimicrob Agents Chemother 2006;50:748–51.
[PubMed: 16436736]
Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and
rimantadine. Curr Top Microbiol Immunol 1992;176:119–30. [PubMed: 1600749]
Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE, Monto AS. Influenza viruses resistant
to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004;190:1627–30.
[PubMed: 15478068]
Hickman D, Hossain MJ, Song H, Araya Y, Solorzano A, Perez DR. An avian live attenuated master
backbone for potential use in epidemic and pandemic influenza vaccines. J Gen Virol 2008;89:2682–
90. [PubMed: 18931063]
Huber VC, Kleimeyer LH, McCullers JA. Live, attenuated influenza virus (LAIV) vehicles are strong
inducers of immunity toward influenza B virus. Vaccine 2008;26:5381–8. [PubMed: 18708106]
Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, Brown EG, Holtzman MJ, Brody SL. Influenza
Virus Receptor Specificity and Cell Tropism in Mouse and Human Airway Epithelial Cells. J Virol
2006;80:7469–80. [PubMed: 16840327]
Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA. Oseltamivir-ribavirin
combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob
Agents Chemother 2008;52:3889–97. [PubMed: 18725448]
Barnard Page 16
Antiviral Res. Author manuscript; available in PMC 2010 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Isoda N, Sakoda Y, Kishida N, Bai GR, Matsuda K, Umemura T, Kida H. Pathogenicity of a highly
pathogenic avian influenza virus, A/chicken/Yamaguchi/7/04 (H5N1) in different species of birds
and mammals. Arch Virol 2006;151:1267–79. [PubMed: 16502281]
Jeffery KT, Ann HR, Thomas AJ, Thomas GF. Integrating historical, clinical and molecular genetic data
in order to explain the origin and virulence of the 1918 Spanish influenza virus. Philos Trans Royal
Soc B: Biol Sci 2001;356:1829–39.
Karaca K, Swayne DE, Grosenbaugh D, Bublot M, Robles A, Spackman E, Nordgren R. Immunogenicity
of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats. Clin
Diagn Lab Immunol 2005;12:1340–2. [PubMed: 16275953]
Katz JM, Lu X, Tumpey TM, Smith CB, Shaw MW, Subbarao K. Molecular correlates of influenza A
H5N1 virus pathogenesis in mice. J Virol 2000a;74:10807–10. [PubMed: 11044127]
Katz JM, Lu X, Frace AM, Morken T, Zaki SR, Tumpey TM. Pathogenesis of and immunity to avian
influenza A H5 viruses. Biomedicine & Pharmacotherapy 2000b;54:178–187.
Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T,
Fouchier RA, Lower J, Osterhaus AD, Sutter G, Rimmelzwaan GF. Recombinant Modified Vaccinia
Virus Ankara Expressing the Hemagglutinin Gene Confers Protection against Homologous and
Heterologous H5N1 Influenza Virus Infections in Macaques. J Infect Dis. 2008Epub ahead of print
Kuiken T, Rimmelzwaan GF, Van Amerongen G, Osterhaus AD. Pathology of human influenza A
(H5N1) virus infection in cynomolgus macaques (Macaca fascicularis). Vet Pathol 2003;40:304–10.
[PubMed: 12724572]
Lambkin R, Oxford JS, Bossuyt S, Mann A, Metcalfe IC, Herzog C, Viret JF, Glück R. Strong local and
systemic protective immunity induced in the ferret model by an intranasal virosome-formulated
influenza subunit vaccine. Vaccine 2004;22:4390–96. [PubMed: 15474733]
Lee I, Barton TD. Viral respiratory tract infections in transplant patients: Epidemiology, recognition and
management. Drugs 2007;67:1411–1427. [PubMed: 17600390]
Lipatov AS, Kwon YK, Sarmento LV, Lager KM, Spackman E, Suarez DL, Swayne DE. Domestic Pigs
Have Low Susceptibility to H5N1 Highly Pathogenic Avian Influenza Viruses. PLoS Pathogens
2008;4:e1000102. [PubMed: 18617994]
Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, Rolland A, Smith LR. Plasmid DNA-based
vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza
virus. J Infect Dis 2008;197:1643–52. [PubMed: 18513153]
Lowen AC, Mubareka S, Tumpey TM, Garcia-Sastre A, Palese P. The guinea pig as a transmission model
for human influenza viruses. PNAS 2006;103:9988–92. [PubMed: 16785447]
Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross
TM. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic
H5N1 influenza viruses. Vaccine 2008;26:5393–9. [PubMed: 18706956]
Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, Greer PW, Nguyen DC, Szretter KJ, Chen LM,
Thawatsupha P, Chittaganpitch M, Waicharoen S, Nguyen DT, Nguyen T, Nguyen HH, Kim JH,
Hoang LT, Kang C, Phuong LS, Lim W, Zaki S, Donis RO, Cox NJ, Katz JM, Tumpey TM. Avian
influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in
mammals. J Virol 2005;79:11788–800. [PubMed: 16140756]
Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV, Mishin VP,
Hayden FG, Kim DH, Ing A, Campbell ER, Yu M, Fang F. Sialidase Fusion Protein as a Novel
Broad-Spectrum Inhibitor of Influenza Virus Infection. Antimicrob Agents Chemother
2006;50:1470–79. [PubMed: 16569867]
Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Human and avian influenza viruses
target different cell types in cultures of human airway epithelium. PNAS 2004;101:4620–24.
[PubMed: 15070767]
McCullers JA, English BK. Improving therapeutic strategies for secondary bacterial pneumonia
following influenza. Future Microbiol 2008;3:397–404. [PubMed: 18651811]
Mizuguchi M, Yamanouchi H, Ichiyama T, Shiomi M. Acute encephalopathy associated with influenza
and other viral infections. Acta Neurol Scand 2007;115:45–56. [PubMed: 17362276]
Monto AS, Arden NH. Implications of viral resistance to amantadine in control of influenza. A Clin Infect
Dis 1992;15:362–7.discussion 368–9
Barnard Page 17
Antiviral Res. Author manuscript; available in PMC 2010 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Morens DM, Taubenberger JK, Fauci AS. Predominant Role of Bacterial Pneumonia as a Cause of Death
in Pandemic Influenza: Implications for Pandemic Influenza Preparedness. J Infect Dis
2008;198:962–70. [PubMed: 18710327]
Mori I, Liu B, Hossain MJ, Takakuwa H, Daikoku T, Nishiyama Y, Naiki H, Matsumoto K, Yokochi T,
Kimura Y. Successful protection by amantadine hydrochloride against lethal encephalitis caused by
a highly neurovirulent recombinant influenza A virus in mice. Virology 2002;303:287–96. [PubMed:
12490390]
Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD
(IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor
Rev 1997;8:207–19. [PubMed: 9462486]
Ottolini MG, Blanco JCG, Eichelberger MC, Porter DD, Pletneva L, Richardson JY, Prince GA. The
cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J Gen
Virol 2005;86:2823–30. [PubMed: 16186238]
Oxford JS, Lambkin R, Guralnik M, Rosenbloom RA, Petteruti MP, Digian K, LeFante C. In vivo
prophylactic activity of QR-435 against H3N2 influenza virus infection. Am J Ther 2007;14:462–8.
[PubMed: 17890936]
Park CH, Ishinaka M, Takada A, Kida H, Kimura T, Ochiai K, Umemura T. The invasion routes of
neurovirulent A/Hong Kong/483/97 (H5N1) influenza virus into the central nervous system after
respiratory infection in mice. Arch Virol 2002;147:1425–36. [PubMed: 12111416]
Parks CL, Latham T, Cahill A, O’Neill RE, Passarotti CJ, Buonagurio DA, Bechert TM, D’Arco GA,
Neumann G, Destefano J, Arendt HE, Obregon J, Shutyak L, Hamm S, Sidhu MS, Zamb TJ, Udem
SA. Phenotypic properties resulting from directed gene segment reassortment between wild-type A/
Sydney/5/97 influenza virus and the live attenuated vaccine strain. Virology 2007;367:275–87.
[PubMed: 17599381]
Peltola VT, Boyd KL, McAuley JL, Rehg JE, McCullers JA. Bacterial Sinusitis and Otitis Media
following Influenza Virus Infection in Ferrets. Infect Immun 2006;74:2562–67. [PubMed: 16622191]
Peiris JSM, de Jong MD, Guan Y. Avian Influenza Virus (H5N1): A Threat to Human Health. Clin
Microbiol Rev 2007;20:243–267. [PubMed: 17428885]
Perrone LA, Plowden JK, Garcia-Sastre A, Katz JM, Tumpey TM. H5N1 and 1918 Pandemic Influenza
Virus Infection Results in Early and Excessive Infiltration of Macrophages and Neutrophils in the
Lungs of Mice. PLoS Pathog 2008;4:e1000115. [PubMed: 18670648]
Pinto CA, Haff RF, Stewart RC. Pathogenesis of and recovery from respiratory syncytial and influenza
infections in ferrets. Arch Gesamte Virusforsch 1969;26:225–37. [PubMed: 5782934]
Potter CW, Phair JP, Vodinelich L, Fenton R, Jennings R. Antiviral, immunosuppressive and antitumour
effects of ribavirin. Nature 1976;259:496–7. [PubMed: 1256547]
Reading PC, Bozza S, Gilbertson B, Tate M, Moretti S, Job ER, Crouch EC, Brooks AG, Brown LE,
Bottazzi B, Romani L, Mantovani A. Antiviral Activity of the Long Chain Pentraxin PTX3 against
Influenza Viruses. J Immunol 2008;180:3391–98. [PubMed: 18292565]
Rimmelzwaan GF, Baars M, van Amerongen G, van Beek R, Osterhaus ADME. A single dose of an
ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge
infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A
(H3N2) viruses. Vaccine 2001;20:158–163. [PubMed: 11567760]
Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, Osterhaus AD. A primate
model to study the pathogenesis of influenza A (H5N1) virus infection. Avian Dis 2003;47:931–3.
[PubMed: 14575089]
Rimmelzwaan GF, van Riel D, Baars M, Bestebroer TM, van Amerongen G, Fouchier RAM, Osterhaus
ADME, Kuiken T. Influenza A Virus (H5N1) Infection in Cats Causes Systemic Disease with
Potential Novel Routes of Virus Spread within and between Hosts. Am J Pathol 2006;168:176–183.
[PubMed: 16400021]
Rosseau S, Hocke A, Mollenkopf H, Schmeck B, Suttorp N, Kaufmann SHE, Zerrahn J. Comparative
transcriptional profiling of the lung reveals shared and distinct features of Streptococcus pneumoniae
and influenza A virus infection. Immunol 2007;120:380–91.
Barnard Page 18
Antiviral Res. Author manuscript; available in PMC 2010 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus ADME. Vaccination of Macaques with Adjuvanted
Formalin-Inactivated Influenza A Virus (H5N1) Vaccines: Protection against H5N1 Challenge
without Disease Enhancement. J Virol 2008;82:2565–2569. [PubMed: 18094159]
Rutigliano JA, Doherty PC, Franks J, Morris MY, Reynolds C, Thomas PG. Screening monoclonal
antibodies for cross-reactivity in the ferret model of influenza infection. J Immunol Method
2008;336:71–7.
Subbarao K, Luke C. H5N1 viruses and vaccines. PLoS Pathog 2007;3:e40. [PubMed: 17335350]
Sidwell RW, Bailey KW, Wong MH, Huffman JH. In vitro and in vivo sensitivity of a non-mouse-adapted
influenza A (Beijing) virus infection to amantadine and ribavirin. Chemotherapy 1995;41:455–61.
[PubMed: 8529436]
Sidwell RW, Smee DF. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral
Res 2000;48:1–16. [PubMed: 11080536]
Sidwell RW, Bailey KW, Morrey JD, Wong MH, Baldwin TJ, Smee DF. Inhibition of influenza virus
infections in immunosuppressed mice with orally administered peramivir (BCX-1812). Antiviral Res
2003;60:17–25. [PubMed: 14516917]
Sidwell RW, Smee DF. Experimental disease models of influenza virus infections: recent developments.
Drug Discov Today Dis Models 2004;1:57–63.
Smee DF, Wong MH, Bailey KW, Sidwell RW. Activities of oseltamivir and ribavirin used alone and in
combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses.
Antivir Chem Chemother 2006;17:185–92. [PubMed: 17066897]
Smee DF, Bailey KW, Wong M-H, O’Keefe BR, Gustafson KR, Mishin VP, Gubareva LV. Treatment
of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res
2008;80:266–271. [PubMed: 18601954]
Smith H, Sweet C. Lessons for human influenza from pathogenicity studies with ferrets. Rev Infect Dis
1988;10:56–75. [PubMed: 3281223]
Smith MW, Schmidt JE, Rehg JE, Orihuela CJ, McCullers JA. Induction of pro- and anti-inflammatory
molecules in a mouse model of pneumococcal pneumonia after influenza. Comp Med 2007;57:82–
9. [PubMed: 17348295]
Speshock JL, Doyon-Reale N, Rabah R, Neely MN, Roberts PC. Filamentous Influenza A Virus Infection
Predisposes Mice to Fatal Septicemia following Superinfection with Streptococcus pneumoniae
Serotype 3. Infect Immun 2007;75:3102–11. [PubMed: 17403870]
Steininger C, Popow-Kraupp T, Laferl H, Seiser A, Godl I, Djamshidian S, Puchhammer-Stockl E. Acute
encephalopathy associated with influenza A virus infection. Clin Infect Dis 2003;36:567–74.
[PubMed: 12594636]
Stertz S, Dittmann J, Blanco JC, Pletneva LM, Haller O, Kochs G. The antiviral potential of interferon-
induced cotton rat Mx proteins against orthomyxovirus (influenza), rhabdovirus, and bunyavirus.
J Interferon Cytokine Res 2007;27:847–55. [PubMed: 17970694]
Stittelaar KJ, Tisdale M, van Amerongen G, van Lavieren RF, Pistoor F, Simon J, Osterhaus AD.
Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in
cynomolgus macaques. Antiviral Res 2008;80:225–8. [PubMed: 18647621]
Straight TM, Ottolini MG, Prince GA, Eichelberger MC. Antibody contributes to heterosubtypic
protection against influenza A-induced tachypnea in cotton rats. Virol J 2008;5:44. [PubMed:
18355405]
Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-[gamma] during
recovery from influenza infection. Nat Med 2008;14:558–64. [PubMed: 18438414]
Svitek N, Rudd PA, Obojes K, Pillet S, von Messling V. Severe seasonal influenza in ferrets correlates
with reduced interferon and increased IL-6 induction. Virology 2008;376:53–9. [PubMed:
18420248]
Szretter KJ, Gangappa S, Lu X, Smith C, Shieh WJ, Zaki SR, Sambhara S, Tumpey TM, Katz JM. Role
of Host Cytokine Responses in the Pathogenesis of Avian H5N1 Influenza Viruses in Mice. J Virol
2007;81:2736–44. [PubMed: 17182684]
Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, Kim CU, Mendel DB. Characterization
of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor
GS 4071. Antimicrob Agents Chemother 1998;42:3234–41. [PubMed: 9835519]
Barnard Page 19
Antiviral Res. Author manuscript; available in PMC 2010 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Taubenberger JK. The origin and virulence of the 1918 “Spanish” influenza virus. Proc Amer Philos Soc
2006;150:86–112. [PubMed: 17526158]
Taubenberger JK, Morens DM. The Pathology of Influenza Virus Infections. Ann Rev Pathol: Mech Dis
2008;3:499–522.
Vahlenkamp TW, Harder TC, Giese M, Lin F, Teifke JP, Klopfleisch R, Hoffmann R, Tarpey I, Beer M,
Mettenleiter TC. Protection of cats against lethal influenza H5N1 challenge infection. J Gen Virol
2008;89:968–74. [PubMed: 18343838]
van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, Oxford J. Animal models in
influenza vaccine testing. Expert Rev Vaccines 2008;7:783–93. [PubMed: 18665776]
van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RAM, Osterhaus ADME, Kuiken T.
H5N1 Virus Attachment to Lower Respiratory Tract. Science 2006;312:399. [PubMed: 16556800]
Vincent AL, Ma W, Lager KM, Janke BH, Webby RJ, Garcia-Sastre A, Richt JA. Efficacy of intranasal
administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine
2007;25:7999–8009. [PubMed: 17933442]
Wang R, Song A, Levin J, Dennis D, Zhang NJ, Yoshida H, Koriazova L, Madura L, Shapiro L,
Matsumoto A, Yoshida H, Mikayama T, Kubo RT, Sarawar S, Cheroutre H, Kato S. Therapeutic
potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res
2008;80:168–177. [PubMed: 18598723]
Wright, PF.; Neumann, G.; Kawaoka, Y. Orthomyxoviruses. In: Knipe, DM.; Howley, PM., editors.
Fields Virology. Vol. 5. Lippincott Williams & Wilkins; Philadelphia: 2007. p. 1691-740.
Xu T, Qiao J, Zhao L, Wang G, He G, Li K, Tian Y, Gao M, Wang J, Wang H, Dong C. Acute Respiratory
Distress Syndrome Induced by Avian Influenza A (H5N1) Virus in Mice. Am J Respir Crit Care
Med 2006;74:1011–17. [PubMed: 16917113]
Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, Govorkova EA.
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and
transmissibility. Antimicrob Agents Chemother 2005;49:4075–84. [PubMed: 16189083]
Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA. Neuraminidase Inhibitor
Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication
Efficiency and Pathogenicity in Vitro and in Vivo. J Virol 2007;81:12418–26. [PubMed: 17855542]
Yun NE, Linde NS, Zacks MA, Barr IG, Hurt AC, Smith JN, Dziuba N, Holbrook MR, Zhang L,
Kilpatrick JM, Arnold CS, Paessler S. Injectable peramivir mitigates disease and promotes survival
in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1).
Virology 2008;374:198–209. [PubMed: 18234269]
Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, Zhang HJ, Chen HL, Wong SS, Lau SK, Woo PC,
Chan KH, Jin DY, Yuen KY. Delayed antiviral plus immunomodulator treatment still reduces
mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S
A 2008;105:8091–6. [PubMed: 18523003]
Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM. Pathogenesis of Avian Influenza A (H5N1)
Viruses in Ferrets. J Virol 2002;76:4420–29. [PubMed: 11932409]
Barnard Page 20
Antiviral Res. Author manuscript; available in PMC 2010 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Barnard Page 21
Table 1
Influenza A virus infections: the basics
Classification and Structure Influenza viruses are spherical or pleomorphic, single-stranded, negative-sense RNA viruses belonging to the
family Orthomyxoviridae. Influenza A and B viruses contain eight separate ribonucleoprotein (RNP) segments,
while influenza C virus contains seven, each of which encodes 1 or 2 proteins. The internal antigens (M1 and NP
proteins) are the type-specific antigens used to determine if a particular virus is A, B or C, while the external
hemagglutinin (HA) and neuraminidase (NA) are the subtype- and strain-specific antigens.
Infection cycle Influenza virus binds to receptors on the surface of the host cell via the HA protein. It is internalized into
endosomes, after which pH-dependent fusion and uncoating release the viral RNPs into the cytoplasm, where
they are transported into the nucleus for replication. Viral messenger RNAs are exported out of the nucleus for
protein synthesis, and some of the resulting proteins are transported back into the nucleus to assist in replication
and RNP assembly. New RNPs assemble with other virus proteins at the M1 matrix to form virions, which bud
from the plasma membrane.
Epidemiology Influenza A viruses cause chronic, asymptomatic infection in the gastrointestinal tracts of wild birds, but are also
able to infect and cause disease in a variety of mammals. Such avian viruses cause a range of illness in humans,
ranging from conjunctivitis through the fulminant illness caused by the recently emerged H5N1 virus. On rare
occasions, an influenza A virus is introduced into human populations and spreads rapidly to cause a global
pandemic. This can occur either when an avian virus with a novel HA protein adapts to human-to-human
transmission, or when an avian virus undergoes genomic reassortment during co-infection of an influenza virus-
infected mammal such as a pig. As a pandemic virus circulates, it undergoes progressive antigenic drift in its HA
and NA proteins, permitting to re-infect the same populations in regular outbreaks of “seasonal” influenza.
Clinical syndromes Symptoms of seasonal influenza typically include high fever, chills, headache, sore throat, dry cough, myalgia,
anorexia, and malaise. Complications include primary viral pneumonia, secondary bacterial pneumonia, or
combined bacterial and viral pneumonia. Severe infections caused by the recently emerged avian influenza A
H5N1 virus are characterized by rapid development of diffuse interstitial pneumonia, viremia and shock leading
to death.
Vaccines Inactivated vaccines (Fluzone®, Fluvirin™) obtained from infected chicken embryos are most commonly used.
Attenuated vaccines include FluMist®.
Approved therapeutics Approved therapeutics for seasonal influenza A virus infections include the neuraminidase inhibitors oseltamivir
phosphate (Tamiflu®) and zanamivir (Relenza®) and the M2 ion channel blockers amantadine (Symmetrel®)
and rimantadine (Flumadine®).
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Table 2
Summary of current animal models available for studying benign disease associated with seasonal influenza
Virus Disease Model Animal Model References
Influenza A strains
Aichi/2/68 (H3N2)
A/NIB/26/90M (H3N2)
A/NIB/23/89M (H1N1)
A/NIB/23/89-MA (mouse adapted
Mild Pathogenesis Mouse
BALB/cJCitMoise (B/c)
A/SnJCitMoise
CBA/CaLacSto
C57BL/6LacSto
Gambaryan et al.,
2005
Influenza
A/Aichi/2/68 (H3N2)
Mild Pathogenesis Ferret Svitek et al., 2008
Influenza A/Port/Chalmers/173 (rat
adapted after 11 passages in rats
Mild Pathogenesis Rat (Rattus) Brown Norway
Fischer-344 Sprague-Dawley
Daniels et al., 2003
Swine influenza A strains:X98 H3N2
A/SW/CO/23619/99 H3N2
A/SW/IA/00239/2004 rH1N1
Mild Pathogenesis Pig Vincent et al.,
2007
Influenza A H1N1
A/Texas/36/91
Mild Pathogenesis/Pneumonia Pigtailed macaque Baas et al., 2006
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Table 3
Summary of currently available animal models for studying severe seasonal influenza pneumonia
Virus Animal Model References
Influenza A H3N2 strains Mouse (BALB/c) Reviewed by Sidwell and Smee, 2000
A/Shangdong/09/93
A/Victoria/3/79
Influenza B strains
B/HongKong/5/72
B/Lee/40
B/Sichuan/379/99 BALB/c Smee et al., 2006
Influenza A H1N1 strains BALB/c Smee et al., 2008
A/WSN/33 (H1N1) virus containing the HA gene of A/New
Caledonia/20/99
A/New Caledonia/20/99 BALB/c Smee et al., 2006
Influenza A strains
A/Charlottesville/31/95 (H1N1) Ferret Smee et al., 2008
A/USSR/90/77 (H1N1) Ferret Svitek et al., 2008
A/Port Chalmers/1/73 (H3N2)
Influenza A H3N2 Cotton Rat Ottolini, 2005, Review by Eichelberger,
2007
A/Wuhan/359/95
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Table 4
Summary of current animal models available for studying models of sepsis associated with influenza virus infections
Virus Bacterial Infection Disease Model Animal Model References
Influenza A H3N2
A/Scotland/20/74
Neisseria meningitidis Sepsis model Mouse (BALB/c) Alonso, 2003
Influenza A H1N1
A/PR/8/34
Streptococcus pneumoniae Sepsis model Mouse (BALB/c) Hayashi, 2006
Influenza A H1N1
A/PR/8/34
Streptococcus pneumoniae Sepsis model Mouse (BALB/c) Smith, 2007
Influenza A H3N2
A/Sydney/5/97
A/Fujian/411/02
Influenza A H1N1
ATaiwan/1/86
Influenza B
B/Singapore/222/79
Streptococcus pneumoniae Secondary bacterial infection
model
Ferret Peltola, 2006
Influenza A H3N2
Wuhan/359/95
Staphylococcus aureus Bacterial synergy model Ferret Braun, 2006
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Table 5
Summary of current animal models available for studying human disease caused by highly pathogenic H5N1 avian
viruses
Virus Disease Model Animal Model References
A/duck/Tuva/01/06 (H5N1) Interstitial pneumonia Mouse (BALB/c) Evenseeko et al., 2007
A/Vietnam/1203/2004
VN1204PB2-627Lys (mutant) (BALB/c) Hatta et al., 2007
A/Vietnam/1204/2004
VN1203PB2-627Glu (mutant)
A/chicken/Vietnam/NCVD5/2003
A/muscovy/duck/Vietnam/
NCVD18/2003
A/Vietnam/1194/04 (BALB/c)
A/Vietnam/1203/04 (VN1203) Hatta and Kawaoka,
2005
A/Vietnam/1204/04 (VN1204)
A/duck/Vietnam/NCVD-5/03
A/duck/Vietnam/NCVD-18/03
A/duck/Vietnam/NCVD-25/03
A/chicken/Vietnam/NCVD-8/03
A/chicken/Vietnam/NCVD-15/03
A/chicken/Vietnam/NCVD-30/03
A/chicken/Yamaguchi/7/04
(BALB/c) Isoda et al., 2006
H5N1 viruses: A/Hong
Kong/481/97 (BALB/c) Katz et al., 2000b
A/HongKong/483/97
A/Hong Kong/485197
A/Hong Kong1486197
A/Hong Kong/507/97
H5N1 viruses: A/ck/HK/220/97 BALB/c Dybing et al., 2000
A/ck/HK/728/97
A/HK/156/97
A/ck/Scotland/59
A/tk/England/91
A/HongKong/156/97 (BALB/c) Gubareva et al., 1998a
Influenza A H5N1 Pathogenesis/Pneumonia Ferret Zitzow, 2002
A/Hong Kong/486/97
A/Hong Kong/483/97
Influenza B clinical isolate related to B/
Beijing/184/93 and B/Guangdong/8/93
Gubareva et al., 1998b
Influenza A H5N1 Pathogenesis/Pneumonia Cat Rimmelzwaan et al.,
2006
Antiviral Res. Author manuscript; available in PMC 2010 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Barnard Page 26
Virus Disease Model Animal Model References
A/Vietnam/1194/04
Influenza A H5N1 Pathogenesis/Pneumonia Cynomolgus macaque Kuiken et al., 2003
A/HongKong/156/97 Rimmelzwaan et al.,
2003
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Table 6
Summary of current animal models available for studying acute respiratory distress syndrome (ARDS) developing in
the setting of H5N1 avian influenza
Virus Animal Model References
Influenza A H5N1
A/Chicken/Hebei/108/2002
Mouse (BALB/c) Xu, 2006
Influenza A H5N1
A/HongKong/156/97
Cynomolgus macaques Kuiken et al., 2003
Rimmelzwaan et al., 2003
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Table 7
Summary of current animal models available for studying influenza virus-associated neurotropic disease
Virus Animal Model References
Influenza A H1N1
A/WSN/33
Mouse (C57BL/6-BJ6) Aronsson, 2003
Influenza A H5N1
Recombinant R404BP
A/WSN/33 X A/Aichi/2/68
Mouse (C57BL/6) Mori, 2002
Influenza A H5N1
A/Hong Kong/483/97
Mouse (BALB/cA Jcl) Park, 2002
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Table 8
Summary of current animal models available for studying drug-resistant influenza virus infections
Virus Animal Model Drug References
Influenza A H4N2
A/turkey/Minnesota/833/80
Mouse (BALB/CBYJ) neuraminidase inhibitors Gubareva, 1997
Influenza A H1N1
NWS/G70C4-G
Mouse (C57BL6 X C57BL10) Ferret zanamivir Blick, 1998
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Table 9
Summary of current animal models available for studying the immunocompromised host infected with influenza virus
Virus Disease Model Animal Model References
Influenza A H1N1, NWS/33 Cyclophosphamide immunosuppression
Immunocompromised mouse
Mouse(BALB/c) SCID Mouse Sidwell, 2003
Influenza A H2N2, Japan/
305/57
Immunocompromised mouse SCID Mouse Ison et al., 2006
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